MatthewAlexanderLunningDO

Hematologic Oncology

Associate Professor

Dr. Lunning is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
987400 Nebraska Medical Ctr
Omaha, NE 68198
Phone+1 402-552-2000

Fax+1 402-552-2512

Dr. Matthew Lunning is an Oncologist based in Omaha, specializing in Hematologic Oncology. He obtained his degree from Des Moines University College of Osteopathic Medicine in 2006, completed his residency in Internal Medicine at the University of Nebraska Medical Center College of Medicine, and a fellowship in Hematology and Medical Oncology at the Memorial Sloan Kettering Cancer Center. His vast experience includes hematologic oncology, hematopoietic stem cell transplantation, hairy cell leukemia, and hodgkin's lymphoma, among others. He has contributed to various publications in esteemed journals. He also participates regularly in clinical trials, mainly in the capacity of Contact or Principal Investigator. Dr. Lunning received the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2013.

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 2006 - 2009
Des Moines University College of Osteopathic MedicineClass of 2006

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data.
Moataz Ellithi, Magdi Elsallab, Matthew A Lunning, Sarah A Holstein, Smriti Sharma
Transplantation and Cellular Therapy. 2025-02-01
Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel.
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sarah Nikiforow, Sairah Ahmed
Blood Advances. 2025-01-30
3 citations
Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John Tamaresis, Armin Ghobadi
Journal of Clinical Oncology. 2024-10-20

Journal Articles

Lectures

Driving Forces in Patient Selection for CAR T-Cell Therapy in Aggressive Lymphoma
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Medical Research Highlights, February 2025February 15th, 2025
$TG Therapeutics, Inc. Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory Diffus$
TG Therapeutics, Inc. Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory DiffusJanuary 4th, 2017